

STIC Biotechnology Systems Branch

RAW SEQUENCE LISTING ERROR REPORT

The Biotechnology Systems Branch of the Scientific and Technical Information Center (STIC) detected errors when processing the following computer readable form:

Application Serial Number:

Source:

Date Processed by STIC:

10/527,662
PE
3-24-05

THE ATTACHED PRINTOUT EXPLAINS DETECTED ERRORS.

PLEASE FORWARD THIS INFORMATION TO THE APPLICANT BY EITHER:

- 1) INCLUDING A COPY OF THIS PRINTOUT IN YOUR NEXT COMMUNICATION TO THE APPLICANT, WITH A NOTICE TO COMPLY or,
- 2) TELEPHONING APPLICANT AND FAXING A COPY OF THIS PRINTOUT, WITH A NOTICE TO COMPLY

FOR CRF SUBMISSION AND PATENTIN SOFTWARE QUESTIONS, PLEASE CONTACT MARK SPENCER, TELEPHONE: 571-272-2510; FAX: 571-273-0221

TO REDUCE ERRORED SEQUENCE LISTINGS, PLEASE USE THE CHECKER VERSION 4.2.2 PROGRAM, ACCESSIBLE THROUGH THE U.S. PATENT AND TRADEMARK OFFICE WEBSITE. SEE BELOW FOR ADDRESS:

<http://www.uspto.gov/web/offices/pac/checker/chkrnote.htm>

Applicants submitting genetic sequence information electronically on diskette or CD-Rom should be aware that there is a possibility that the disk/CD-Rom may have been affected by treatment given to all incoming mail.

Please consider using alternate methods of submission for the disk/CD-Rom or replacement disk/CD-Rom.

Any reply including a sequence listing in electronic form should NOT be sent to the 20231 zip code address for the United States Patent and Trademark Office, and instead should be sent via the following to the indicated addresses:

1. EFS-Bio (<<http://www.uspto.gov/ebc/efs/downloads/documents.htm>> , EFS Submission User Manual - cPAVE)
2. U.S. Postal Service: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450
3. Hand Carry, Federal Express, United Parcel Service, or other delivery service (EFFECTIVE 01/14/05):
U.S. Patent and Trademark Office, Mail Stop Sequence, Customer Window, Randolph Building, 401 Dulany Street, Alexandria, VA 22314

Revised 01/24/05

Sequence Listing Error Summary

ERROR DETECTED

SUGGESTED CORRECTION

SERIAL NUMBER: 10/527/662

ATTN: NEW RULES CASES: PLEASE DISREGARD ENGLISH "ALPHA" HEADERS, WHICH WERE INSERTED BY PTO SOFTWARE

1 Wrapped Nucleics
Wrapped Aminos The number/text at the end of each line "wrapped" down to the next line. This may occur if your file was retrieved in a word processor after creating it. Please adjust your right margin to .5; this will prevent "wrapping."

2 Invalid Line Length The rules require that a line not exceed 72 characters in length. This includes white spaces.

3 Misaligned Amino
Numbering The numbering under each 5' amino acid is misaligned. Do not use tab codes between numbers; use space characters, instead.

4 Non-ASCII The submitted file was not saved in ASCII(DOS) text, as required by the Sequence Rules. Please ensure your subsequent submission is saved in ASCII text.

5 Variable Length Sequence(s) contain n's or Xaa's representing more than one residue. Per Sequence Rules, each n or Xaa can only represent a single residue. Please present the maximum number of each residue having variable length and indicate in the <220>-<223> section that some may be missing.

6 PatentIn 2.0
"bug" A "bug" in PatentIn version 2.0 has caused the <220>-<223> section to be missing from amino acid sequence(s). Normally, PatentIn would automatically generate this section from the previously coded nucleic acid sequence. Please manually copy the relevant <220>-<223> section to the subsequent amino acid sequence. This applies to the mandatory <220>-<223> sections for Artificial or Unknown sequences.

7 Skipped Sequences
(OLD RULES) Sequence(s) missing. If intentional, please insert the following lines for each skipped sequence:
(2) INFORMATION FOR SEQ ID NO X (insert SEQ ID NO where "X" is shown)
(i) SEQUENCE CHARACTERISTICS (Do not insert any subheadings under this heading)
(ii) SEQUENCE DESCRIPTION SEQ ID NO X (insert SEQ ID NO where "X" is shown)
This sequence is intentionally skipped

Please also adjust the "(ii) NUMBER OF SEQUENCES" response to include the skipped sequences.

8 Skipped Sequences
(NEW RULES) Sequence(s) missing. If intentional, please insert the following lines for each skipped sequence:
<210> sequence id number
<400> sequence id number
000

9 Use of n's or Xaa's
(NEW RULES) Use of n's and/or Xaa's have been detected in the Sequence Listing.
Per 1.823 of Sequence Rules, use of <220>-<223> is MANDATORY if n's or Xaa's are present.
In <220> to <223> section, please explain location of n or Xaa, and which residue n or Xaa represents.

10 Invalid <213>
Response Per 1.823 of Sequence Rules, the only valid <213> responses are Unknown, Artificial Sequence, or scientific name (Genus/species). <220>-<223> section is required when <213> response is Unknown, or is Artificial Sequence.

11 Use of <220>

Use of <220> to <223> is MANDATORY if <213> "Organism" response is "Artificial Sequence" or "Unknown." Please explain source of genetic material in <220> to <223> section.
(See "Federal Register," 00/01/1998, Vol. 63, No. 104, pp. 29631-32) (Sec. 1.823 of Sequence Rules)

12 PatentIn 2.0
"bug"

Please do not use "Copy to Disk" function of PatentIn version 2.0. This causes a corrupted file, resulting in missing mandatory numeric identifiers and responses (as indicated on raw sequence listing). Instead, please use "File Manager" or any other manual means to copy file to floppy disk.

13 Misuse of n/Xaa "n" can only represent a single nucleotide; "Xaa" can only represent a single amino acid.

AMC - Biotechnology Systems Branch - 07/09/2003

Best Available Copy



PCT

RAW SEQUENCE LISTING

DATE: 03/24/2005

PATENT APPLICATION: US/10/527,662

TIME: 11:10:21

Input Set : A:\sequence listing.txt

Output Set: N:\CRF4\03242005\J527662.raw

5 <110> APPLICANT: Vlaams Interuniversitair Instituut voor Biotechnologie vzw
 9 <120> TITLE OF INVENTION: A method for the identification of drug targets
 13 <130> FILE REFERENCE: JVK-ChP-V127

C--> 17 <140> CURRENT APPLICATION NUMBER: US/10/527,662

C--> 17 <141> CURRENT FILING DATE: 2005-03-11

17 <150> PRIOR APPLICATION NUMBER: EP 02078801.4

19 <151> PRIOR FILING DATE: 2002-09-12

23 <160> NUMBER OF SEQ ID NOS: 8

27 <170> SOFTWARE: PatentIn version 3.1

31 <210> SEQ ID NO: 1

33 <211> LENGTH: 5

35 <212> TYPE: PRT

37 <213> ORGANISM: Artificial Sequence

41 <220> FEATURE:

43 <223> OTHER INFORMATION: Peptide used in figure 3B and is acetylated.

45 <400> SEQUENCE: 1

47 Phe Ile Glu Gly Arg

48 1 5

51 <210> SEQ ID NO: 2

53 <211> LENGTH: 11

55 <212> TYPE: PRT

57 <213> ORGANISM: Artificial Sequence

61 <220> FEATURE:

63 <223> OTHER INFORMATION: The peptide used in example 1.2: has an acetylated free
 alpha-NH2

64 terminus and a free COOH-terminus.

66 <400> SEQUENCE: 2

68 Phe Ile Glu Gly Arg Ala Asp Ser Lys Ser Ser

69 1 5 10

72 <210> SEQ ID NO: 3

74 <211> LENGTH: 10

76 <212> TYPE: PRT

78 <213> ORGANISM: Artificial Sequence

82 <220> FEATURE:

84 <223> OTHER INFORMATION: The peptide in example 1.3; the Asp group carries an
 aldehyde, th

85 e first Ala is acetylated.

87 <400> SEQUENCE: 3

89 Ala Ala Ile Glu Gly Arg Tyr Val Ala Asp

90 1 5 10

93 <210> SEQ ID NO: 4

95 <211> LENGTH: 4

97 <212> TYPE: PRT

99 <213> ORGANISM: Artificial Sequence

See item # 11 on
 error summary sheet 3/24/05

103 <220> FEATURE:

RAW SEQUENCE LISTING

PATENT APPLICATION: US/10/527,662

DATE: 03/24/2005

TIME: 11:10:21

Input Set : A:\sequence listing.txt

Output Set: N:\CRF4\03242005\J527662.raw

105 <223> OTHER INFORMATION: The peptide in example 1.3; the Asp group carries an aldehyde, th

106 e Tyr is acetylated.

108 <400> SEQUENCE: 4

110 Tyr Val Ala Asp

111 1

114 <210> SEQ ID NO: 5

116 <211> LENGTH: 6

118 <212> TYPE: PRT

120 <213> ORGANISM: Artificial Sequence

124 <220> FEATURE:

126 <223> OTHER INFORMATION: The peptide used in example 1.5 and Lys carries 19-actin-50.

128 <400> SEQUENCE: 5

130 Ala Asp Ser Lys Ser Ser

131 1 5

134 <210> SEQ ID NO: 6

136 <211> LENGTH: 5

138 <212> TYPE: PRT

140 <213> ORGANISM: Artificial Sequence

144 <220> FEATURE:

146 <223> OTHER INFORMATION: Peptide used in example 1.5; sequence from the compound peptide.

148 <220> FEATURE:

150 <221> NAME/KEY: MISC_FEATURE

152 <222> LOCATION: (4)..(4)

154 <223> OTHER INFORMATION: XAA can be any amino acid.

158 <400> SEQUENCE: 6

W--> 160 Ala Asp Ser Xaa Ser

161 1 5

164 <210> SEQ ID NO: 7

166 <211> LENGTH: 9

168 <212> TYPE: PRT

170 <213> ORGANISM: Artificial Sequence

174 <220> FEATURE:

176 <223> OTHER INFORMATION: Peptide used in example 1.5; sequence derived from 19-27 actin se

177 quence.

179 <400> SEQUENCE: 7

181 Ala Gly Phe Ala Gly Asp Asp Ala Pro

182 1 5

185 <210> SEQ ID NO: 8

187 <211> LENGTH: 5

189 <212> TYPE: PRT

191 <213> ORGANISM: Artificial Sequence

195 <220> FEATURE:

197 <223> OTHER INFORMATION: The peptide is used in example 1.6: the NH2-terminal part of the

198 compound peptide; the Phe is acetylated.

200 <400> SEQUENCE: 8

202 Phe Ile Glu Glu Arg

203 1 5

INVALID response

See item #11 on error summary sheet.

SAME error

SAME error

SAME error

SAME error

RAW SEQUENCE LISTING ERROR SUMMARY
PATENT APPLICATION: US/10/527,662

DATE: 03/24/2005
TIME: 11:10:22

Input Set : A:\sequence listing.txt
Output Set: N:\CRF4\03242005\J527662.raw

Please Note:

Use of n and/or Xaa have been detected in the Sequence Listing. Please review the Sequence Listing to ensure that a corresponding explanation is presented in the <220> to <223> fields of each sequence which presents at least one n or Xaa.

Seq#:6; Xaa Pos. 4 ✓

VERIFICATION SUMMARY

PATENT APPLICATION: US/10/527,662

DATE: 03/24/2005

TIME: 11:10:22

Input Set : A:\sequence listing.txt

Output Set: N:\CRF4\03242005\J527662.raw

L:17 M:270 C: Current Application Number differs, Replaced Current Application No

L:17 M:271 C: Current Filing Date differs, Replaced Current Filing Date

L:160 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:6 after pos.:0